Zealthy vs Henry Meds: Genetic Insights for Personalized GLP-1 Selection

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Zealthy and Henry Meds represent two popular telehealth platforms offering GLP-1 medications for weight management and metabolic health. Both companies have grown rapidly, with Zealthy emphasizing personalized nutrition coaching and Henry Meds focusing on streamlined medical assessment. Yet despite their accessibility, many patients still struggle to know which platform—and which medication—will work best for their unique biology.

Full head-to-head: PlexusDx vs Henry Meds →

The critical gap lies not in convenience but in precision. Recent research shows that genetic variants in GLP-1 receptor pathways, FTO genes, and MC4R signaling can influence both medication efficacy and side-effect tolerance. Choosing between Zealthy, Henry Meds, or other telehealth providers becomes more informed when you understand your genetic predispositions in these peptide pathways. PlexusDx bridges this gap by combining compounded GLP-1 medications with genetic insights to guide the selection process.

Zealthy vs Henry Meds: Platform Models and Service Scope

Zealthy operates as a comprehensive wellness platform, coupling GLP-1 prescriptions with nutrition coaching, meal planning, and ongoing lifestyle support. The company employs a nutrition-first philosophy, positioning GLP-1 as one component of a broader metabolic intervention. Consultations typically involve assessments with nurse practitioners or physicians, followed by structured coaching sessions.

Henry Meds takes a leaner, direct-to-consumer approach. The platform prioritizes rapid assessment and medication delivery, with less emphasis on coaching. Patients complete an online questionnaire, speak briefly with a provider, and receive a prescription—often within 24–48 hours. Henry Meds appeals to patients seeking efficiency and lower monthly costs, though ongoing support is minimal compared to Zealthy's holistic model.

Medication Options, Pricing, and Genetic Fit Framework

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Dimension	Zealthy	Henry Meds	PlexusDx Approach
Primary Focus	Holistic wellness + nutrition coaching	Fast assessment + direct prescription	Compounded medications + genetic insights
Medication Types	Semaglutide injections (primary)	Compounded semaglutide (injection or sublingual); tirzepatide as oral dissolving tablet only (as of July 2026)	Compounded semaglutide, tirzepatide, microdose protocols
Pricing Range	$299–$599/month, per Zealthy’s published rates — verify on Zealthy’s site	Injectable semaglutide $297/mo month-to-month (advertised $197/mo = 12-month prepaid); oral semaglutide $249/mo; oral tirzepatide 3-month supply $1,047 ($891 paid in full)	$129–$389/mo depending on protocol
Genetic Testing	Not routinely offered	Not routinely offered	Precision Peptide Genetic Test ($298)
Ongoing Support	Nutrition coaching included	Minimal after prescription	Provider access + genetic interpretation support

How Genetic Predispositions Shape GLP-1 Response and Selection

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

When Zealthy or Henry Meds providers assess a patient, they evaluate medical history, current medications, and comorbidities—but without genetic context, they often rely on trial-and-error dosing. A patient with a GLP1R variant associated with high receptor sensitivity might tolerate a lower starting dose better, whereas a patient with FTO variants predisposing to stronger appetite drive might benefit from dual-action tirzepatide over single-action semaglutide. Genetic testing cannot guarantee outcomes, but it can support a more informed initial medication choice.

Clinical Safety, Eligibility Screening, and Provider Oversight

Both Zealthy and Henry Meds require basic health screening: blood pressure checks, assessment of contraindications (personal or family history of thyroid cancer, multiple endocrine neoplasia type 2, pregnancy), and often baseline metabolic labs. Henry Meds tends to complete this assessment quickly and asynchronously, while Zealthy integrates it into a longer consultation. Neither platform requires in-person evaluation, which increases access but may miss nuanced clinical details relevant to genetic ancestry, kidney function, or drug-drug interactions.

PlexusDx works exclusively with licensed 503A compounding pharmacies to ensure medication quality and regulatory compliance. Patients undergo a similar eligibility screen but receive additional guidance interpreting their Precision Peptide Genetic Test results with their provider. This dual framework—genetic insight plus compounded medication options—allows for more granular dose customization and reduced starting-dose side effects compared to brand-name fixed-dose pens.

Genetic Predisposition Testing and Personalization Framework

The Precision Peptide Genetic Test analyzes your variants in GIPR and FTO, and MC4R pathways. Results reveal your genetic predisposition profile—how your body's appetite-regulating and hormone-sensitivity genes are wired—but do not predict exact medication response. Interpreting these variants requires a qualified healthcare provider familiar with peptide physiology. A genetic predisposition toward high GLP-1 receptor sensitivity, for example, may point toward lower-dose initiation or oral formulations over injections.

Zealthy and Henry Meds do not currently offer genetic testing, so their providers must rely on standard clinical assessment alone. PlexusDx integrates genetic insight as an optional add-on (standalone $298 with compounded medication orders). When you understand your peptide genetic background, you and your provider can make a more targeted initial medication choice, potentially reducing trial-and-error cycles and improving tolerability.

How PlexusDx Supports a More Personalized Approach

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

PlexusDx's Precision Peptide Genetic Test reveals your predispositions in these four key pathways. Results are not deterministic—they cannot guarantee that a particular medication will work—but they can support a more personalized conversation between you and your healthcare provider. This genetic context, paired with PlexusDx compounded semaglutide, tirzepatide, or microdose protocols, allows for tailored dosing and formulation selection from the outset.

If you are comparing Zealthy or Henry Meds with PlexusDx, consider whether genetic personalization matters to your decision. Both telehealth platforms offer rapid access and established prescriber networks. PlexusDx differentiates by combining compounded medication flexibility with optional genetic testing, enabling a more precision-wellness approach to GLP-1 therapy initiation and dose optimization.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Zealthy and Henry Meds?

Zealthy emphasizes holistic wellness with integrated nutrition coaching and longer consultations, while Henry Meds prioritizes speed and cost efficiency with minimal post-prescription support. Zealthy's programs center on GLP-1 medications with coaching; Henry Meds' weight program dispenses compounded GLP-1 medications — its tirzepatide is an oral dissolving tablet only, as of July 2026 — in one all-inclusive cash-pay subscription. Neither routinely includes genetic testing.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Genetic testing reveals predispositions in peptide pathways that may inform medication selection, but it cannot guarantee exact response. Results should be interpreted with a qualified healthcare provider to support a more informed initial choice alongside clinical assessment.

How does PlexusDx pricing compare to Zealthy or Henry Meds?

PlexusDx compounded semaglutide is $189/mo month-to-month, or from $149/mo on the 6-month plan; compounded tirzepatide at $289/mo. Pricing depends on formulation and compounding complexity. As of July 2026, Henry Meds lists injectable compounded semaglutide at $297/month month-to-month (the advertised “$197/month” is its 12-month prepaid-in-full rate), oral sublingual semaglutide at $249/month, and oral tirzepatide dissolving tablets as a 3-month supply at $1,047 ($891 paid in full). Zealthy typically ranges $299–$599/month per its published rates — verify on Zealthy's site — with nutrition coaching included.

Are compounded GLP-1 medications from PlexusDx as safe as brand-name versions?

PlexusDx sources all compounded medications from licensed 503A pharmacies, which operate under FDA oversight and USP standards. Compounded formulations are not FDA-approved but follow equivalent quality and sterility protocols. Your provider and pharmacist can discuss safety and suitability for your individual health profile.

What does the Precision Peptide Genetic Test from PlexusDx reveal?

The test analyzes GIPR and FTO, and MC4R variants to reveal your predispositions in GLP-1 receptor sensitivity, dual-peptide response, baseline appetite regulation, and appetite-circuit signaling. Results should be interpreted with your healthcare provider and may support more personalized medication selection conversations.

Related Reading

• Henry Meds Glp 1
• Henry Meds Tirzepatide
• Henry Meds Cost
• Trimrx Vs Henry Meds Vs Plexusdx

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.